(Reuters) -Merck & Co said on Thursday it would buy Acceleron Pharma Inc for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring ...

Merck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond its immuno-oncology megablockbuster Keytruda, but ...

Which large pharma company is preparing to splash $11 billion to acquire Acceleron? That is the question raised by an article in Bloomberg, which reports an unidentified large pharma company is in ...

Merck said Sept. 30 it will acquire Acceleron Pharma for about $11.5 billion to expand its rare disease drug portfolio. Merck will pay Acceleron $180 per share in cash. Acceleron develops drugs to ...

Merck's new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks into his tenure, though, his company was already in talks for its ...

– Sotatercept received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) in PAH in 2019 – – In the spring of 2020, sotatercept received Breakthrough Therapy designation from the ...

Merck announced on Nov. 22 that it completed its $11.5 billion acquisition of Acceleron Pharma Inc. “This is an important and strategic opportunity for our company to continue growing our ...

The webcast will include Acceleron’s senior management team along with the STELLAR trial’s principal investigator, Marius Hoeper, M.D. 1 Dr. Hoeper is a Professor and Senior Physician in the ...

- Event to be webcast on Tuesday, June 22 at 8:00 a.m. EDT - Members of the Acceleron leadership team, along with external experts, will review the Company’s numerous ongoing and planned trials in ...